Results 101 to 110 of about 25,910 (264)

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients

Genome Medicine
Background Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II epitopes and ...
Xiuli Zhang, S. Peter Goedegebuure, Michael Y. Chen, Rashmi Mishra, Felicia Zhang, Yik Yeung Yu, Kartik Singhal, Lijin Li, Feng Gao, Nancy B. Myers, Tammi Vickery, Jasreet Hundal, Michael D. McLellan, Mark A. Sturmoski, Samuel W. Kim, Ina Chen, Jesse T. Davidson, Narendra V. Sankpal, Stephanie Myles, Rama Suresh, Cynthia X. Ma, Ademuyiwa Foluso, Andrea Wang-Gillam, Sherri Davies, Ian S. Hagemann, Elaine R. Mardis, Obi Griffith, Malachi Griffith, Christopher A. Miller, Ted H. Hansen, Timothy P. Fleming, Robert D. Schreiber, William E. Gillanders   +32 more
doaj   +1 more source

Artificial Intelligence for Identifying Tumor‐Reactive CD8+ T Cells: Biological Principles, Computational Advances, and Future Directions

Med Research, EarlyView.
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang, Yingying Sun, Yan Zhang, Yifen Shi, Zhiwen Shi   +4 more
wiley   +1 more source

Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity

Journal for ImmunoTherapy of Cancer
Background Tumor neoantigen vaccines typically require multiple prime-boost immunizations over several weeks or even months to elicit sufficient neoantigen-specific T-cell responses, which greatly limits their effectiveness against rapidly progressing ...
Ling Li, Yongyi Zeng, Zhenli Li, Geng Chen, Zhixiong Cai, Xiaolong Liu, Xiuqing Dong, Ruijing Tang, Kongying Lin, Luobin Guo, Pan Mou, Peizhe Chen, Junjing Huang   +12 more
doaj   +1 more source

Mapping Tumor Recurrence and Metastasis With Pan‐Cancer Multi‐Omics

Med Research, EarlyView.
Tumor recurrence and metastasis arise from the interaction of shared evolutionary programs and context‐dependent modifiers. Clonal evolution, including genomic instability, subclonal selection, and treatment pressure, interacts with reversible cell‐state plasticity involving partial EMT, stemness, and dormancy, whereas immune escape, stromal remodeling,
Wenjun Meng, Ruicen Li, Xiaoli Mu, Xiaolong Tang, Yuxi Luo, Yingying Lei, Jinghong Xian, Guiyi Ji, Yihao Liu, Chenyu Huo, Sihan Li, Yalun Li, Jiadi Gan, Weimin Li   +13 more
wiley   +1 more source

Aptamer–Based Targeted Protein Degradation: Mechanistic Principles, Delivery Strategies, and Translational Opportunities

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik, Suyeon Son, Jaesung Lee, Ki Soo Park   +3 more
wiley   +1 more source

Cancer immunotherapy targeting neoantigens

Seminars in Immunology, 2016
Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few years have suggested a key role for neoantigens in cancer immunotherapy. Here we review the discoveries of neoantigens in the past two decades and the current advances in neoantigen identification.
Lu, Yong-Chen, Robbins, Paul F.
openaire   +2 more sources

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer

, 2018
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells.
Yuji Ikeda, Yusuke Nakamura, Tatsuo Matsuda, Makiko Harada, Gini F. Fleming, Jae-Hyun Park, Ernst Lengyel, Taigo Kato, Matthias Leisegang, Lili Ren, Kazuma Kiyotani   +10 more
core   +1 more source

Molecular, spatial, and AI‐enabled technologies for predicting neoadjuvant therapy response in locally advanced rectal cancer

The Journal of Pathology, EarlyView.
Abstract Pretreatment prediction of neoadjuvant response remains an unresolved challenge in locally advanced rectal cancer, where management is moving towards risk‐adapted and response‐oriented treatment strategies. Prediction remains difficult because response reflects interacting tumour‐intrinsic, immune, stromal, and spatial processes that are ...
Gina F Boot, Cibele Masotti, Claudia Corrò, Cédric Schraepen, Hannah L Williams, Thomas A Wright, Fiza Ishaqwala, Colin W Steele, Gertjan Rasschaert, Maxime W Lafarge, Enric Domingo, Inti Zlobec, Rodrigo Oliva Perez, Campbell SD Roxburgh, Timothy S Maughan, Sabine Tejpar, Thibaud Koessler, Viktor H Koelzer   +17 more
wiley   +1 more source

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

, 2018
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses1,2 and can function as bona fide antigens that facilitate tumour rejection3.
Eric S. Lander, Neuberg, Donna, Olsen, Lars R., Anita Giobbie-Hurder, Pelton, Kristine, Mathewson, Nathan D., Hu, Zhuting, Daley, Heather, McCluskey, Christine, Wucherpfennig, Kai W., William J. Lane, Sachet A. Shukla, Christine McCluskey, Heather Daley, Wen, Patrick Y., Shukla, Sachet A., Ritz, Jerome, Catherine J. Wu, Lander, Eric S., Alyssa R. Richman, Annabelle J. Anandappa, Wandi Zhang, Patrick A. Ott, Sara Abdelrahman, Charbonneau, Sarah, Chiocca, E. Antonio, Li, Letitia, Giacomo Oliveira, Oriol Olive, Iorgulescu, Julian, Aviv Regev, Salazar, Andres M., Monika S. Kowalczyk, Keskin, Derin B., Lane, William, Allesøe, Rosa Lundbye, Harden, Maegan, Liudmila Elagina, Iorgulescu, J. Bryan, Felt, Kristen, Zhang, Wandi, Wucherpfennig, Kai, Ligon, Keith L., Lennon, Niall J., Andres M. Salazar, Ott, Patrick A, Kai W. Wucherpfennig, Jonathan Stevens, Sulva, Mario, Tirosh, Itay, Elagina, Liudmila, Shuqiang Li, Gad Getz, Stacey Gabriel, Kristen Felt, Edward F. Fritsch, Jing Sun, Itay Tirosh, Scott J. Rodig, Lander, Eric Steven, Getz, Gad Asher, Zhuting Hu, Olive, Oriol, Le, Phuong M., Li, Shuqiang, Mathewson, Nathan, David A. Reardon, Regev, Aviv, Mario L. Suvà, Lane, William J., Patrick Y. Wen, Geduldig, Jack E., Stevens, Jonathan, Wu, Catherine J, Derin B. Keskin, Jerome Ritz, Anandappa, Annabelle J., Sarah Charbonneau, Lars R. Olsen, Kenneth J. Livak, Kristine Pelton, Oliveira, Giacomo, Jack E. Geduldig, Nathan D. Mathewson, Kowalczyk, Monika S, Suvà, Mario L., Evisa Gjini, Wu, Catherine, Letitia Li, Olsen, Lars Rønn, Nir Hacohen, Phuong M. Le, Lennon, Niall, Fritsch, Edward F., Giobbie-Hurder, Anita, Keskin, Derin, Richman, Alyssa R., Allesøe, Rosa L., Rodig, Scott J., Hacohen, Nir, Rosa L. Allesøe, Livak, Kenneth J, Keith L. Ligon, Gabriel, Stacey, Abdelrahman, Sara, Reardon, David A., E. Antonio Chiocca, J. Bryan Iorgulescu, Maegan Harden, Wu, Catherine J., Niall J. Lennon, Livak, Kenneth J., Donna Neuberg, Kowalczyk, Monika S., Sun, Jing, Ott, Patrick A., Gjini, Evisa, Getz, Gad   +117 more
core   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source